[目的]探讨甲硫氨酸维B1治疗肝硬化的临床效果及对患者肝功能,症状及并发症的影响.[方法]回顾性分析2013年3月至2016年3月本院收治的肝硬化患者80例临床资料.38例患者采用常规处理方法进行治疗(对照组),42例患者在常规治疗基础上使用甲硫氨酸维B1进行治疗(观察组),观察比较两组患者治疗效果及其生化指标的变化.[结果]① 治疗前,两组患者肝功能指标[总胆红素(TBIL)、谷丙转氨酶(ALT)、胆碱酯酶(CHE)、纤维结合蛋白(FN)]及肝纤维化血清学指标值[透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、层粘连蛋白(LN)、Ⅳ型胶原(cⅣ)]无明显差异性(P>0.05);治疗后,观察组患者上述指标值明显优于对照组(P<0.05).②观察组治疗总有效率明显高于对照组(P<0.05).③观察组患者并发症发生率明显低于对照组(P<0.05).[结论]甲硫氨酸维B1能显著改善肝硬化患者肝功能及症状,值得在临床上进一步推广和使用.“,”[Objective]To study on the efficiency of methionine and vitaminB1 in the treatment of hepatic cirrhosis and their effects on liver function, symptoms and complications.[Methods]From March 2013 to March 2016, there were 80 patients with hepatocirrhosis treated in our hospital.Their clinical data were analyzed retrospectively.Among them, 38 patients were treated by the traditional method (the control group).On the basis of traditional method, 42 patients received Methionine and VitaminB1 treatment (the experimental group).The effects of these treatments were observed and compared between the two groups.[Results] (1) Before treatment, there were no significant differences in liver function (i.e.TBIL, ALT, CHE, FN) and serum liver fibrosis (HA、PCⅢ、LN、cⅣ) between the experimental and controls (P<0.05).After treatment, the indicators stated above in the experimental group were significantly lower than those in the control group (P<0.05);(2) The total effective rate of the experimental group was higher than that of the control group (85.71% VS 71.05%) (P<0.05);(3) The incidence of complications (liver and kidney syndrome, hepatic encephalopathy, spontaneous bacterial peritonitis) in the experimental group was significantly lower than that in the control group (9.52% VS 26.32%) (P<0.05).[Conclusion]Methionine and VitaminB1 can significantly improve the liver function and symptoms.The treatment is safe and effective.Therefore, this method is worthy of further promotion and use in clinic.